Literature DB >> 15525474

Norcantharidin induces apoptosis in HeLa cells through caspase, MAPK, and mitochondrial pathways.

Wei-wei An1, Xian-feng Gong, Min-wei Wang, Shin-ichi Tashiro, Satoshi Onodera, Takashi Ikejima.   

Abstract

AIM: To investigate the mechanism of norcantharidin (NCTD)-induced HeLa cell apoptosis.
METHODS: HeLa cell growth inhibition was measured by MTT method. Apoptosis was detected by Hoechst 33258 staining and agarose gel electrophoresis. Caspase activities were assayed using caspase apoptosis detection kit. Western blot analysis was used to evaluate the level of ICAD, ERK/p-ERK, JNK/p-JNK, and Bcl-X(L)/Bax expression.
RESULTS: Norcantharidin inhibited HeLa cell growth in a time- and dose-dependent manner. HeLa cells treated with norcantharidin showed typical characteristics of apoptosis including the morphological changes and DNA fragmentation. Caspase family inhibitor (z-VAD-fmk), caspase-8, -9 inhibitor (z-IETD-fmk, Ac-LEHD-CHO, respectively) and caspase-3 inhibitor (z-DEVD-fmk) partially prevent norcantharidin-induced apoptosis, but initiator caspase-1 inhibitor (Ac-YVAD-fmk) did not. The activities of caspase-3, -8, and -9 were up-regulated after norcantharidin treatment. Furthermore, NCTD-induced activation of caspase-3 resulted in the degradation of the inhibitor of caspase-activated DNase (ICAD). Up-regulation of mitochondrial Bax expression and down-regulation of Bcl-x(L) expression also participated in the apoptosis induced by NCTD. Although p38 MAPK inhibitor (SB203580) failed to block cell death, ERK MAPK inhibitor (PD98059) and JNK MAPK inhibitor (SP600125) had marked inhibitory effects on norcantharidin-induced apoptosis. Moreover, the phosphorylation of JNK were up-regulated followed by delayed ERK phosphorylation after treatment with NCTD, suggesting that ERK and JNK were both responsible for NCTD-induced apoptosis in HeLa cells and worked at different stages.
CONCLUSION: The cytotoxic effect of NCTD on HeLa cells was mainly due to apoptosis. The anti-tumor mechanism of NCTD might involve caspses, mitochondrial, and MAPKs pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15525474

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  7 in total

Review 1.  Norcantharidin, a protective therapeutic agent in renal tubulointerstitial fibrosis.

Authors:  Ying Li; Yan Ge; Fu You Liu; You Ming Peng; Lin Sun; Jun Li; Qiong Chen; Yan Sun; Kun Ye
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

2.  Norcantharidin Inhibits SK-N-SH Neuroblastoma Cell Growth by Induction of Autophagy and Apoptosis.

Authors:  Zeping Han; Baoxia Li; Juanjuan Wang; Xiangqiang Zhang; Zhenhua Li; Liting Dai; Mingrong Cao; Jianwei Jiang
Journal:  Technol Cancer Res Treat       Date:  2016-07-08

3.  Norcantharidin inhibits Wnt signal pathway via promoter demethylation of WIF-1 in human non-small cell lung cancer.

Authors:  Junran Xie; Yaping Zhang; Xuming Hu; Ran Lv; Dongju Xiao; Li Jiang; Qi Bao
Journal:  Med Oncol       Date:  2015-03-27       Impact factor: 3.064

4.  Norcantharidin Induces HL-60 Cells Apoptosis In Vitro.

Authors:  You-Ming Jiang; Zhen-Zhi Meng; Guang-Xin Yue; Jia-Xu Chen
Journal:  Evid Based Complement Alternat Med       Date:  2012-06-24       Impact factor: 2.629

Review 5.  Bee Venom-A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections.

Authors:  Keneth Iceland Kasozi; Gniewko Niedbała; Mohammed Alqarni; Gerald Zirintunda; Fred Ssempijja; Simon Peter Musinguzi; Ibe Michael Usman; Kevin Matama; Helal F Hetta; Ngala Elvis Mbiydzenyuy; Gaber El-Saber Batiha; Amany Magdy Beshbishy; Susan Christina Welburn
Journal:  Front Public Health       Date:  2020-12-10

6.  Norcantharidin induced DU145 cell apoptosis through ROS-mediated mitochondrial dysfunction and energy depletion.

Authors:  Bo Shen; Pei-Jie He; Chun-Lin Shao
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

Review 7.  Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities.

Authors:  Mu-Su Pan; Jin Cao; Yue-Zu Fan
Journal:  Chin Med       Date:  2020-05-29       Impact factor: 5.455

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.